Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

Circulating blood is filtered across the glomerular barrier to form an ultrafiltrate of plasma in
the Bowman's space. The volume of glomerular filtration adjusted by time is defined as the …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

SGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD).
But the mechanism for such protection is not clear. Here, we report that in damaged proximal …

Background: Sodium-glucose cotransporter-2 inhibitors improve heart failure–related
outcomes. The mechanisms underlying these benefits are not well understood, but diuretic …